About the Company
talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
125
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TALS News
Aclaris Therapeutics Inc ACRS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish
Tourmaline Bio went public via a reverse merger with Talaris Therapeutics, Inc. in October last year, 2023, and although the share price initially nosedived to $10 per share, it quickly picked up ...
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic ...
ALGS Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug ...
Patrick G Enright's Net Worth
Who is Patrick G Enright? Patrick G Enright has an estimated net worth of $1.94 Billion. This is based on reported shares across multiple companies, which include VALENTIS INC, Inozyme Pharma, Inc ...
Clarus Lifesciences III, L.P.'s Net Worth
Who is Clarus Lifesciences III, L.P.? Clarus Lifesciences III, L.P. has an estimated net worth of $230 Million. This is based on reported shares across multiple companies, which include Imago ...
Aquestive Therapeutics, Inc. (AQST)
As of 1:27 PM EDT. Market Open. WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Axsome Therapeutics Inc AXSM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Viking Therapeutics Inc (VKTX)
On Tuesday, Viking Therapeutics (NASDAQ:VKTX) saw its price target increased by an Oppenheimer analyst to $138 from the previous $116, while the stock's rating remains at... On Tuesday, Viking ...
Q4 2023 Inhibikase Therapeutics Inc Earnings Call
Milton Werner; President & CEO; Inhibikase Therapeutics, Inc. Garth Lees-Rolfe; CFO; Inhibikase Therapeutics, Inc. Operator Ladies and gentlemen, thank you for standing by Greetings and welcome to ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Loading the latest forecasts...